Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
President Obama signed the Patient Protection and Affordable Care Act (PPACA) in to law in March 2010 after a year of intense national debate. On Thursday last week, the U.S. Supreme Court upheld law, ruling that the individual mandate, which requires U.S. citizens and legal residents to have qualifying health coverage or pay a penalty, is constitutional as a tax. The ruling will have a far-reaching impact on healthcare providers, especially for those who work with underserved populations.